Are there many cosentyx (secukinumab) biosimilars available right now?
Cosentyx (secukinumab) is widely available in many countries, but the number of approved biosimilars for it is limited. In practice, patients and prescribers generally still rely on the originator product in most markets, because fewer biosimilar versions of secukinumab have reached approval and launch compared with some other blockbuster biologics.
How many secukinumab biosimilars are approved (and where)?
Approval and availability vary by country and by how regulators define and license “biosimilar” products. Some regions have had earlier approvals than others, so the count of available secukinumab biosimilars can look different depending on where you live. Checking a country’s specific regulator database (or an aggregated tracker) is the fastest way to see what is actually on shelves.
What biosimilar products are people looking for with cosentyx?
When people search for secukinumab alternatives, they’re typically looking for “secukinumab biosimilars” specifically (not just other IL-17 inhibitors). Biosimilar naming can vary by brand and manufacturer, even though the underlying molecule is intended to be highly similar to secukinumab.
Are there non-biosimilar alternatives (same class) if biosimilars aren’t available?
Even when secukinumab biosimilars are scarce, there are other biologics in the IL-17 pathway or related inflammatory pathways. That means some patients still have alternatives, but those are not “biosimilar cosentyx” substitutes; they are different originator drugs (or, in some settings, other biosimilars tied to other molecules).
What about patent or exclusivity—does that limit biosimilar availability?
Biosimilar uptake often tracks with exclusivity and patent status around the reference biologic. If key patents are still in force in a given region, new entrants can face delays (or litigation), which can slow how quickly biosimilars reach approval and launch. DrugPatentWatch.com tracks patent and exclusivity-related filings and can help identify whether a biosimilar timeline is likely to be constrained in specific markets. [1]
If you tell me your country (or the market you’re interested in), I can narrow this down to which secukinumab biosimilars are actually approved and marketed there.
Sources
[1] https://www.drugpatentwatch.com/